Geneaire ReBuilder™ a New Class of Supplement
We would all like to live longer, but most people are equally concerned with the quality of their life as they age. They are looking for increased “healthspan,” not just “lifespan.” Those of us in our later years have all probably experienced a “senior moment” or two, and are concerned about how to limit degradation in memory and brain function as we grow older.
Although there are many “remedies,” from brain exercises to supplements derived from stranger things like jellyfish, few take advantage of the latest available science. Fortunately, the result of over 30 years of scientific research and clinical trials, right here in Orange County, has recently resulted in the availability of a totally new class of compounds to help us.
Geneaire ReBuilder™ is the culmination of this research at UC Irvine, Genescient Inc, and Hoag Hospital. It is specifically targeted at stabilizing the longevity of neural/brain cells and resisting degradation caused by aging and its related disease.
But Geneaire ReBuilder™ is also very different from a traditional pharmaceutical product that typically targets a specific disease with a single, manufactured component. Due to side effects and other factors, such drugs are subject to industry practices and government approvals and frequently cost hundreds of millions or billions of dollars to bring to market over a typical 5-10-year time frame.
Geneaire ReBuilder™ is the first of a new class of accuceutical product that bridges the gap between these extremes. Its development has been based on decades of scientific research at accredited institutions, using the latest techniques such as advanced genomics, cloud-based analytics, and AI modeling. This research was tested with an extremely successful clinical trial, and the formula has been inactive and successful use for over three years.
Because the product is entirely created from industry-standard “GRAS List” compounds (Generally Considered As Safe), testing and clinical trials are able to be completed much faster than typical pharmaceutical trials, making the time to availability much shorter — and the product consequently much more affordable.
Geneaire ReBuilder™ is a new class of supplement to address brain function degradation problems associated with general aging and the diseases linked to it. It is a complex supplement made from a patented formulation of 13 interacting compounds selected from the Federal Drug Administration’s GRAS List (Generally Regarded as Safe) and is suitable for long-term daily use with a focus on early prevention of brain deterioration, rather than as a cure for an already diagnosed disease. It should be noted that this approach is directly aligned with the latest draft guidelines from the (FDA) to pharmaceutical manufacturers searching for a cure to Alzheimer’s Disease: “Early Alzheimer’s Disease: Developing Drugs for Treatment — Guidance for Industry.” In these draft guidelines, the FDA acknowledges that Stage 1 and Stage 2 Alzheimer’s Disease is very difficult to detect and often occurs years or decades before later stage symptoms become evident. It encourages the pharmaceutical industry to focus on clinical trials and treatments that address these early stages. Several observers have noted the practical and ethical problems of both conducting these early-stage trials and in developing and prescribing drugs for use long before the onset of obvious symptoms. Geneaire ReBuilder™ is focused on mitigating the neurological effects of aging rather than being a cure for a specific disease.
Research during the last 10 years has led Genescient to the development of a formula consisting of multiple, interacting compounds that stimulate the expression of the hundreds of genomic sites responsible for brain function. In doing so they have pieced together the multi-dimensional “neural jigsaw puzzle” that seems to be responsible for the maintenance of the fundamental cellular biology of the brain. Stopping the degradation of the brain’s cellular processes during aging is now thought to be the key to preventing degeneration and promoting longevity. It is also apparent that this stimulation is most effective if addressed during the early stages of aging, which makes any long-term treatment with conventional pharmaceuticals difficult to justify from safety, cost and ethical perspectives. Geneaire ReBuilder™ is the commercially available supplement of the exclusively licensed, patented formula from Genescient’s research. The product is composed entirely of the same natural and safe components from the FDA’s GRAS List. Of course, users should always check with their physician before use. Geneaire is able to provide a supplement that has no reported side effects* that has benefited from accelerated clinical testing and has been made available much faster than a typical pharmaceutical solution. Geneaire’s process means they have been able to keep the product affordable and widely available without a prescription, through mainstream retail sales outlets such as Amazon.
Geneaire ReBuilder™ Research
THE METHUSELAH FLIES
The common fruit fly (Drosophila Melanogaster) has been used for genetics research since the inception of the discipline in the early 20th century. In the 90s it was the obvious choice to study the genomics of aging, mainly because its short lifespan enabled it to be studied over a large number of generations.
Researchers at UCI and other institutions have been able to extend the flies’ lifespan by selective breeding – by only allowing the longer-lived flies in each generation (the “old breeders”) to mate.
Over the years, repeated selective breeding results were very successful. By 2018, researchers had created a special generation of fruit flies with three times the lifespan of normal flies.
WHY FRUIT FLIES?
Flies have a short lifespan, making multi-generation study and research feasible.
There is an 80% overlap in fruit fly and human genomes.
Cellular Functions related to aging are the same between species.
Genome Analysis using AI Machine Learning and Cloud Analytics
Over the last 10 years or so, the combination of the availability of practical Genome Analysis (Genomics) with the development of new Cloud-based Analytics and AI Machine Learning tools has enabled the UCI and Genescient scientists to expand and accelerate their research. Their specific focus is the causes of age-related brain function deterioration and the quest for compounds that can stabilize or prevent it.
Comparison of the Methuselah and normal fruit fly genome sequences indicates that aging is intrinsically a complex process, with several thousand genome sequence variations discovered between the two species variants. Using the new numerical analysis tools to identify active versus passive sequences, over 500 genomic sites have been identified as significantly changed during Methuselah Fly evolution.
It appears that the aging process fundamentally affects biology at the cellular level, and problems caused by the cells’ declining ability to perform basic functions such as waste product excretion more seriously affect brain function than at other body sites. For example, it has long been known that disruptions in brain cell function frequently lead to short- and long-term memory loss.
Identifying Solution Candidates
The search for compounds that can potentially activate or influence these genomic sites has also been assisted by the latest computer techniques. AI-based machine learning and analytics are used to comb a vast amount of published research and other documentation for potential substance candidates, resulting in the identification of both core compounds and combinations of multiple compounds that promise effectiveness in specific formulations.
Most importantly, the compounds in these formulations are all present in natural substances and can be derived from “GRAS List” components (Generally Recognized As Safe). This delivers several major advantages including a reduction in the time to perform effective clinical trials (the compounds induce far fewer side effects) and the removal of the requirement to participate in the very lengthy FDA approval process. The result is a greatly reduced time to availability and reduction in development cost which makes potential products much more affordable than pharmaceutical solutions.
Testing the Hypotheses
Fruit fly research also plays an important role in testing potential compounds: flies are selectively bred with genomes modified with age-related diseases, then used as test subjects for likely compound candidates.
Focus to date has been on specific diseases such as Alzheimer’s, Dementia, Parkinson’s and Vascular Degeneration. Additional research is ongoing.
This ongoing fruit fly research led to the development of a specific and patented formula that, by 2013, was ready to be clinically tested on human patients.
A 15-month clinical study was conducted by Hoag Hospital (2013 – 2015) to test the effect of this formula on a population of mild and moderate Alzheimer patients.
More information is available at www.geneaire.com
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Geneaire ReBuilder™ is now available on Amazon Prime.
It costs less than $2 per day.
www.geneaire.com
